Stochastic asymmetric repartition of lytic machinery in dividing CD8+ T cells generates heterogeneous killing behavior

  1. Fanny Lafouresse  Is a corresponding author
  2. Romain Jugele
  3. Sabina Müller
  4. Marine Doineau
  5. Valérie Duplan-Eche
  6. Eric Espinosa
  7. Marie-Pierre Puissegur
  8. Sébastien Gadat
  9. Salvatore Valitutti
  1. Centre de Recherche en Cancérologie de Toulouse, France
  2. Toulouse School of Economics, UMR 5604, France
  3. Centre de Physiopathologie de Toulouse Purpan, France

Abstract

Cytotoxic immune cells are endowed with a high degree of heterogeneity in their lytic function, but how this heterogeneity is generated is still an open question. We therefore investigated if human CD8+ T cells could segregate their lytic components during telophase, using imaging flow cytometry, confocal microscopy and live cell imaging. We show that CD107a+-intracellular vesicles, perforin and granzyme B unevenly segregate in a constant fraction of telophasic cells during each division round. Mathematical modeling posits that unequal lytic molecule inheritance by daughter cells results from the random distribution of lytic granules on the two sides of the cleavage furrow. Finally, we establish that the level of lytic compartment in individual CTL dictates CTL killing capacity. Together, our results show the stochastic asymmetric distribution of effector molecules in dividing CD8+ T cells. They propose uneven mitotic repartition of pre-packaged lytic components as a mechanism generating non-hereditary functional heterogeneity in CTL.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Fanny Lafouresse

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    For correspondence
    fanny.lafouresse@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6572-8631
  2. Romain Jugele

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Sabina Müller

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Marine Doineau

    Mathematics of decision making and statistics, Toulouse School of Economics, UMR 5604, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Valérie Duplan-Eche

    INSERM, UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Eric Espinosa

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Marie-Pierre Puissegur

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Sébastien Gadat

    Mathematics of decision making and statistics, Toulouse School of Economics, UMR 5604, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Salvatore Valitutti

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.

Funding

Laboratoire d'Excellence Toulouse Cancer (ANR11-LABEX)

  • Salvatore Valitutti

Region occitanie (RCLE R14007BB,671 34 No 12052802,and RBIO R15070BB,No 14054342)

  • Salvatore Valitutti

Fondation Toulouse Cancer Santé (2014CS044)

  • Salvatore Valitutti

Ligue Contre le Cancer (équipe labellisée)

  • Salvatore Valitutti

Ligue Contre le Cancer (4th year phD)

  • Romain Jugele

Bristol-Myers Squibb (No CA184-575)

  • Salvatore Valitutti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Buffy coats of healthy donors were obtained through the Etablissement Français du Sang (EFS, Toulouse, France). Blood samples were collected and processed following standard ethical procedures (Helsinki 433 protocol), after obtaining written informed consent from each donor and approval by the French Ministry of the Research (transfer agreement AC-2014-2384). Approbation by the ethical department of the French Ministry of the Research for the preparation and conservation of cell lines and clones starting from healthy donor human blood samples has been obtained (authorization No DC-2018-3223).

Reviewing Editor

  1. Ellen A Robey, University of California, Berkeley, United States

Publication history

  1. Received: September 2, 2020
  2. Accepted: January 8, 2021
  3. Accepted Manuscript published: January 11, 2021 (version 1)
  4. Version of Record published: February 6, 2021 (version 2)
  5. Version of Record updated: February 10, 2021 (version 3)

Copyright

© 2021, Lafouresse et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,032
    Page views
  • 158
    Downloads
  • 4
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Fanny Lafouresse
  2. Romain Jugele
  3. Sabina Müller
  4. Marine Doineau
  5. Valérie Duplan-Eche
  6. Eric Espinosa
  7. Marie-Pierre Puissegur
  8. Sébastien Gadat
  9. Salvatore Valitutti
(2021)
Stochastic asymmetric repartition of lytic machinery in dividing CD8+ T cells generates heterogeneous killing behavior
eLife 10:e62691.
https://doi.org/10.7554/eLife.62691
  1. Further reading

Further reading

    1. Immunology and Inflammation
    Lyra O Randzavola, Paige M Mortimer ... David C Thomas
    Research Article

    EROS (Essential for Reactive Oxygen Species) protein is indispensable for expression of gp91phox, the catalytic core of the phagocyte NADPH oxidase. EROS deficiency in humans is a novel cause of the severe immunodeficiency, chronic granulomatous disease (CGD), but its mechanism of action was unknown until now. We elucidate the role of EROS, showing it acts at the earliest stages of gp91phox maturation. It binds the immature 58kDa gp91phox directly, preventing gp91phox degradation and allowing glycosylation via the oligosaccharyltransferase (OST) machinery and the incorporation of the heme prosthetic groups essential for catalysis. EROS also regulates the purine receptors P2X7 and P2X1 through direct interactions and P2X7 is almost absent in EROS deficient mouse and human primary cells. Accordingly, lack of murine EROS results in markedly abnormal P2X7 signalling, inflammasome activation and T cell responses. The loss of both ROS and P2X7 signalling leads to resistance to influenza infection in mice. Our work identifies EROS as a highly selective chaperone for key proteins in innate and adaptive immunity and a rheostat for immunity to infection. It has profound implications for our understanding of immune physiology, ROS dysregulation and possibly gene therapy.

    1. Computational and Systems Biology
    2. Immunology and Inflammation
    Mingyao Pan, Bo Li
    Short Report Updated

    T cells are potent at eliminating pathogens and playing a crucial role in the adaptive immune response. T cell receptor (TCR) convergence describes T cells that share identical TCRs with the same amino acid sequences but have different DNA sequences due to codon degeneracy. We conducted a systematic investigation of TCR convergence using single-cell immune profiling and bulk TCRβ-sequence (TCR-seq) data obtained from both mouse and human samples and uncovered a strong link between antigen-specificity and convergence. This association was stronger than T cell expansion, a putative indicator of antigen-specific T cells. By using flow-sorted tetramer+ single T cell data, we discovered that convergent T cells were enriched for a neoantigen-specific CD8+ effector phenotype in the tumor microenvironment. Moreover, TCR convergence demonstrated better prediction accuracy for immunotherapy response than the existing TCR repertoire indexes. In conclusion, convergent T cells are likely to be antigen-specific and might be a novel prognostic biomarker for anti-cancer immunotherapy.